HOME >> BIOLOGY >> NEWS
Columbia researcher identifies cellular defect that may contribute to autism

NEW YORK, NY, January 27 The causes of autism have long remained a mystery, but new research from Columbia University Medical Center has identified, for the first time, how a cellular defect may be involved in the often crippling neurological disorder.

The research, which is published in today's issue of Science, examines how a defect in neuroligin genes may contribute to autism. Neuroligins are components of synapses, which connect individual neurons in the brain. The researchers found that the loss of neuroligins perturbs the formation of neuronal connections and results in an imbalance of neuronal function. This imbalance provides an explanation for the neurodevelopmental defects in autistic children.

"Understanding the cellular defects that may underlie autism-spectrum disorders represents an important step towards the goal of providing therapies," said Peter Scheiffele, Ph.D., assistant professor of physiology and cellular biophysics at Columbia University Medical Center, and principal investigator on the study.

A defect in the neuroligin genes had previously been observed in autistic patients, but its functional significance was not yet understood. Scheiffele's study showed that in rat neurons without any neuroligin, connections between neurons are altered in a way that is strikingly similar to those found in autistic children.

Each neuron in the brain receives many different inputs some are excitatory and signal the neuron to fire, and some are inhibitory and signal the neuron to stop firing. Scheiffele's research team found that neuroligin genes are responsible for regulating the balance between excitatory and inhibitory synaptic function. A defect in neuroligin leads to a selective loss in inhibitory function and thereby impairs the fine-tuning of neuronal connectivity, a neurological problem that is understood to play a role in autism.

"There is much we still don't know about how neurons con
'"/>

Contact: Craig LeMoult
cel2113@columbia.edu
212-305-0820
Columbia University Medical Center
27-Jan-2005


Page: 1 2

Related biology news :

1. Columbia University Medical Center awarded $3 million to drive Alzheimers genetics research
2. Columbia scientists determine 3-dimensional structure of cells fuel gauge
3. Columbia University licenses next-generation DNA sequencing technology
4. New bird discovered on unexplored Columbian mountain
5. Columbia University Medical Center receives major new NIH Clinical Science investment funds
6. Columbia University awards 2006 Horwitz Prize to biologist who explained gene transcription
7. Columbia University receives $16.9 million NIEHS award to study arsenic in ground water
8. Contaminants linked to sturgeon decline in Columbia river
9. Columbia University Medical Center researchers discover potential mechanism for tumor growth
10. UF, Columbia scientists closer to new cancer detection method
11. Columbia University awards 2005 Horwitz Prize to Israeli structural biologist

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) announced that, ... the size of the offering by 75% and purchase 3,684,212 ... to purchase 1,842,106 shares of common stock of the Company ... stock (the "Exercise Price"), at a price to the public ... The warrants have a term of four (4) years, exercisable ...
(Date:1/24/2017)... , ... January 24, 2017 , ... ... circumference, and increased serum leptin levels had a positive association with increased prostate ... study published in the International Neurourology Journal involved 571 Korean men who ...
(Date:1/24/2017)... Franklin, MA, USA & Geneva, Switerland (PRWEB) , ... ... ... are pleased to announce the first commercially available malaria Plasmodium falciparum culture panels ... Malaria P. falciparum culture panels, which are available in a range of concentrations ...
(Date:1/24/2017)... , Jan. 24, 2017 /PRNewswire/ - ProMetic Life Sciences ... announced today that its orally active lead drug candidate, ... designation by the UK Medicines and Healthcare Products Regulatory ... A PIM designation is an early ... for the Early Access to Medicines Scheme ("EAMS"), intended ...
Breaking Biology Technology:
Cached News: